Vitamin D, hydroxyapatite, and calcium gluconate in treatment of cortical bone thinning in postmenopausal women with primary biliary cirrhosis
- PMID: 6287835
- DOI: 10.1093/ajcn/36.3.426
Vitamin D, hydroxyapatite, and calcium gluconate in treatment of cortical bone thinning in postmenopausal women with primary biliary cirrhosis
Abstract
Women with primary biliary cirrhosis malabsorb calcium, phosphate and vitamin D, and develop accelerated cortical bone thinning. We have assessed the value of parenteral vitamin D, oral hydroxyapatite (HA), and calcium gluconate (CG) in the treatment of cortical bone thinning in primary biliary cirrhosis. Sixty-four postmenopausal women with primary biliary cirrhosis were assigned randomly into three groups: one group receiving no mineral supplements (control), one group receiving HA, and one group receiving CG. All patients received parenteral vitamin D2 (100,000 IU monthly). Eleven patients withdrew from the study and 10 withdrew due to poor compliance (six HA, four CG). Over a 14-month follow-up period, none of the groups showed a significant change in serum calcium or inorganic phosphate levels. Pre- and posttreatment hand radiographs were used to assess changes in metacarpal cortical thickness using the technique of caliper radiogrammetry. Cortical bone loss occurred in the control group (p less than 0.01). The HA group showed a significant gain in cortical bone thickness (p less than 0.01), while no significant change occurred in the CG group. This study indicated that vitamin D2 does not halt metacarpal cortical bone thinning in primary biliary cirrhosis. The addition of CG prevents bone thinning, and HA promotes positive cortical bone balance.
Similar articles
-
A 4-year treatment with clodronate plus calcium and vitamin D supplements does not improve bone mass in primary biliary cirrhosis.Dig Liver Dis. 2007 Jun;39(6):544-8. doi: 10.1016/j.dld.2007.02.005. Epub 2007 Apr 6. Dig Liver Dis. 2007. PMID: 17416215 Clinical Trial.
-
Hepatic osteodystrophy in primary biliary cirrhosis: effects of medical treatment.Am J Gastroenterol. 1994 Jan;89(1):47-50. Am J Gastroenterol. 1994. PMID: 8273797
-
Bone disease in primary biliary cirrhosis: increased bone resorption and turnover in the absence of osteoporosis or osteomalacia.Hepatology. 1984 Jan-Feb;4(1):1-8. doi: 10.1002/hep.1840040101. Hepatology. 1984. PMID: 6693061
-
Metabolic Bone Disease in Primary Biliary Cirrhosis.Gastroenterol Clin North Am. 2016 Jun;45(2):333-43. doi: 10.1016/j.gtc.2016.02.009. Gastroenterol Clin North Am. 2016. PMID: 27261902 Review.
-
Bone disease in patients with primary biliary cirrhosis.Prog Liver Dis. 1990;9:537-54. Prog Liver Dis. 1990. PMID: 2156313 Review. No abstract available.
Cited by
-
Microcrystalline hydroxyapatite compound in prevention of bone loss in corticosteroid-treated patients with chronic active hepatitis.Postgrad Med J. 1985 Sep;61(719):791-6. doi: 10.1136/pgmj.61.719.791. Postgrad Med J. 1985. PMID: 2997764 Free PMC article. Clinical Trial.
-
Comparison of the treatment effects of ossein-hydroxyapatite compound and calcium carbonate in osteoporotic females.Osteoporos Int. 1995 Jan;5(1):30-4. doi: 10.1007/BF01623655. Osteoporos Int. 1995. PMID: 7703621 Clinical Trial.
-
Hepatic osteodystrophy: vitamin D metabolism in patients with liver disease.Gut. 1986 Sep;27(9):1073-90. doi: 10.1136/gut.27.9.1073. Gut. 1986. PMID: 3530896 Free PMC article. Review. No abstract available.
-
Non-hormonal treatment of osteoporosis.Br Med J (Clin Res Ed). 1983 Mar 26;286(6370):999-1000. doi: 10.1136/bmj.286.6370.999. Br Med J (Clin Res Ed). 1983. PMID: 6403196 Free PMC article. No abstract available.
-
Non-hormonal treatment of osteoporosis.Br Med J (Clin Res Ed). 1983 May 21;286(6378):1647-8. Br Med J (Clin Res Ed). 1983. PMID: 6405923 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical